Gene related to migraine in man
AssigneeRijksuniversiteit te Leiden
InventorsRune Frants, Michel Ferrari, Gisela Terwindt, Roel Ophoff
Life of this patent
Estimating the term…
Abstract
Genes for familial hemeplegic migraine (FHM), episodic ataxia type-2 (EA-2), common forms of migraine, and other episodic neurological disorders, such as epilepsy, have been mapped to chromosome 19p13. A brain-specific P/Q type calcium channel subunit gene, covering 300 kb with 47 exons is provided. The exons and their surroundings reveal polymorphic variations and deleterious mutations that are linked to various types of cation channel dysfunctions causing episodic neurological disorders in man or animals.
Claims40
An isolated nucleic acid encoding an α1 subunit of a P/O-type gated calcium channel or a specific fragment or homolog or derivative of said calcium channel.
The nucleic acid according to claim 38, wherein said one or more mutation is at a codon in said nucleic acid which results in an amino acid change in said calcium channel respectively selected from the group consisting of codon 192:
- replacement of arginine by glutamine:
- codon 666:
- a replacement of threonine by methionine:
- codon 714, a replacement of valine by alanine;
- and codon 1811:
- a replacement of isoleucine by leucine.
An isolated nucleic acid encoding a calcium channel subunit or a functional fragment thereof, wherein said nucleic acid is obtained from a mammal diagnosed as having one or both of familial hemiplegic migraine and episodic ataxia type 2.
A method for screening for an agent useful for treating FHM, EA-2, SCA6, migraine or other neurological disorder associated with cation channel dysfunction, said method comprising:
- comparing phenotypic characteristics relating to cation channel dysfunction of a first animal contacted with said agent with those of a second animal not contacted with said agents wherein the genome of said first animal and said second animal comprise a nucleic acid encoding dysfunctional α1 subunit of a P/Q-type gated calcium channel, whereby an agent useful for treating FHM, EA-2, SCA6, migraine or other neurological disorder is identified by a decrease in phenotypic characteristics relating to calcium channel dysfunction in said first transgenic mouse in comparison to said second transgenic mouse.
A method for diagnosing FHM, EA-2, SCA6, migraine or other neurological disorders associated with cation channel dysfunction, said method comprising:
- detecting a protein or a peptide encoded by the nucleic acid according to claim 38 in a patient.
A non-human animal with phenotypic characteristics relating to calcium channel dysfunction, the genome of which comprises:
- a nucleic acid encoding dysfunctional α1 subunit of a P/Q-type gated calcium channel.
Dependencies are inferred from the claim text.